Literature DB >> 22473973

Prenatal immune challenge in rats: altered responses to dopaminergic and glutamatergic agents, prepulse inhibition of acoustic startle, and reduced route-based learning as a function of maternal body weight gain after prenatal exposure to poly IC.

Charles V Vorhees1, Devon L Graham, Amanda A Braun, Tori L Schaefer, Matthew R Skelton, Neil M Richtand, Michael T Williams.   

Abstract

Prenatal maternal immune activation has been used to test the neurodevelopmental hypothesis of schizophrenia. Most of the data are in mouse models; far less is available for rats. We previously showed that maternal weight change in response to the immune activator polyinosinic-polycytidylic acid (Poly IC) in rats differentially affects offspring. Therefore, we treated gravid Harlan Sprague-Dawley rats i.p. on embryonic day 14 with 8 mg/kg of Poly IC or Saline. The Poly IC group was divided into those that lost or gained the least weight, Poly IC (L), versus those that gained the most weight, Poly IC (H), following treatment. The study design controlled for litter size, litter sampling, sex distribution, and test experience. We found no effects of Poly IC on elevated zero maze, open-field activity, object burying, light-dark test, straight channel swimming, Morris water maze spatial acquisition, reversal, or shift navigation or spatial working or reference memory, or conditioned contextual or cued fear or latent inhibition. The Poly IC (H) group showed a significant decrease in the rate of route-based learning when visible cues were unavailable in the Cincinnati water maze and reduced prepulse inhibition of acoustic startle in females, but not males. The Poly IC (L) group exhibited altered responses to acute pharmacological challenges: exaggerated hyperactivity in response to (+)-amphetamine and an attenuated hyperactivity in response to MK-801. This model did not exhibit the cognitive, or latent inhibition deficits reported in Poly IC-treated rats but showed changes in response to drugs acting on neurotransmitter systems implicated in the pathophysiology of schizophrenia (dopaminergic hyperfunction and glutamatergic hypofunction).
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22473973      PMCID: PMC3370146          DOI: 10.1002/syn.21561

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  70 in total

1.  The use of behavioral test batteries, II: effect of test interval.

Authors:  Richard Paylor; Corinne M Spencer; Lisa A Yuva-Paylor; Sandra Pieke-Dahl
Journal:  Physiol Behav       Date:  2005-09-28

2.  Maternal immune activation during pregnancy increases limbic GABAA receptor immunoreactivity in the adult offspring: implications for schizophrenia.

Authors:  M Nyffeler; U Meyer; B K Yee; J Feldon; I Knuesel
Journal:  Neuroscience       Date:  2006-10-11       Impact factor: 3.590

Review 3.  Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia.

Authors:  Urs Meyer; Joram Feldon; Manfred Schedlowski; Benjamin K Yee
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

4.  Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring.

Authors:  Lee Zuckerman; Ina Weiner
Journal:  J Psychiatr Res       Date:  2005-05       Impact factor: 4.791

5.  The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia.

Authors:  H Ashdown; Y Dumont; M Ng; S Poole; P Boksa; G N Luheshi
Journal:  Mol Psychiatry       Date:  2006-01       Impact factor: 15.992

6.  Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia.

Authors:  Kimiyoshi Ozawa; Kenji Hashimoto; Takashi Kishimoto; Eiji Shimizu; Hiroshi Ishikura; Masaomi Iyo
Journal:  Biol Psychiatry       Date:  2005-10-26       Impact factor: 13.382

7.  Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism.

Authors:  S H Fatemi; D A Pearce; A I Brooks; R W Sidwell
Journal:  Synapse       Date:  2005-08       Impact factor: 2.562

8.  Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning.

Authors:  Anne-Maj Samuelsson; Eva Jennische; Hans-Arne Hansson; Agneta Holmäng
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-12-15       Impact factor: 3.619

9.  The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology.

Authors:  Urs Meyer; Myriel Nyffeler; Andrea Engler; Adrian Urwyler; Manfred Schedlowski; Irene Knuesel; Benjamin K Yee; Joram Feldon
Journal:  J Neurosci       Date:  2006-05-03       Impact factor: 6.167

Review 10.  Behavioral phenotyping of transgenic and knockout mice: practical concerns and potential pitfalls.

Authors:  Kathleen R Bailey; Nathan R Rustay; Jacqueline N Crawley
Journal:  ILAR J       Date:  2006
View more
  21 in total

1.  Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.

Authors:  Thiago Garcia Varga; Juan Guilherme de Toledo Simões; Amanda Siena; Elisandra Henrique; Regina Cláudia Barbosa da Silva; Vinicius Dos Santos Bioni; Aline Camargo Ramos; Tatiana Rosado Rosenstock
Journal:  Psychopharmacology (Berl)       Date:  2021-06-05       Impact factor: 4.530

2.  Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.

Authors:  Shinnyi Chou; Sean Jones; Ming Li
Journal:  Brain Res       Date:  2015-06-03       Impact factor: 3.252

3.  Variability in PolyIC induced immune response: Implications for preclinical maternal immune activation models.

Authors:  Milo Careaga; Sandra L Taylor; Carolyn Chang; Alex Chiang; Katherine M Ku; Robert F Berman; Judy A Van de Water; Melissa D Bauman
Journal:  J Neuroimmunol       Date:  2018-06-28       Impact factor: 3.478

4.  Altered serine/threonine kinase activity in schizophrenia.

Authors:  Jennifer L McGuire; John H Hammond; Stefani D Yates; Dongquan Chen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Brain Res       Date:  2014-04-26       Impact factor: 3.252

Review 5.  Neuroinflammation as a risk factor for attention deficit hyperactivity disorder.

Authors:  Geoffrey A Dunn; Joel T Nigg; Elinor L Sullivan
Journal:  Pharmacol Biochem Behav       Date:  2019-05-16       Impact factor: 3.533

Review 6.  Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome.

Authors:  Isobel W Green; Jill R Glausier
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

7.  Prenatal immune challenge in rats: effects of polyinosinic-polycytidylic acid on spatial learning, prepulse inhibition, conditioned fear, and responses to MK-801 and amphetamine.

Authors:  Charles V Vorhees; Devon L Graham; Amanda A Braun; Tori L Schaefer; Matthew R Skelton; Neil M Richtand; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2014-11-08       Impact factor: 3.763

8.  Disruption of social approach by MK-801, amphetamine, and fluoxetine in adolescent C57BL/6J mice.

Authors:  Sheryl S Moy; Randal J Nonneman; Geoffrey O Shafer; Viktoriya D Nikolova; Natallia V Riddick; Kara L Agster; Lorinda K Baker; Darin J Knapp
Journal:  Neurotoxicol Teratol       Date:  2012-08-07       Impact factor: 3.763

Review 9.  Cincinnati water maze: A review of the development, methods, and evidence as a test of egocentric learning and memory.

Authors:  Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2016-08-18       Impact factor: 3.763

Review 10.  Evidence for a dysregulated immune system in the etiology of psychiatric disorders.

Authors:  Sinead M Gibney; Hemmo A Drexhage
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.